絞り込み

16645

広告

「世界で最も美しい」クラゲに114年ぶり新種…毒も強烈? (読売新聞)

114年ぶりに発見された新種のデイゴハナガサクラゲ(戸篠さん提供) 世界で最も美しいクラゲとされる「ハナガサクラゲ」の新種を黒潮生物研究所(高知県大月町西泊)の...

  1. 新型肺炎で中国全土に「渡航注意」 外務省...
  2. 日銀や欧州中央銀などデジタル通貨研究へ ...
  3. SF小説『三体』に見る天文学最前線 (日...
  4. 特集:『三体』の科学 (日経サイエンス)...

ニュース一覧

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.

著者 Tai YT , Lin L , Xing L , Cho SF , Yu T , Acharya C , Wen K , Hsieh PA , Dulos J , van Elsas A , Munshi N , Richardson P , Anderson KC
Leukemia.2018 Aug 22 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (18view , 0users)

Full Text Sources

Medical

We investigate here how APRIL impacts immune regulatory T cells and directly contributes to the immunosuppressive multiple myeloma (MM) bone marrow (BM) microenvironment. First, APRIL receptor TACI expression is significantly higher in regulatory T cells (Tregs) than conventional T cells (Tcons) from the same patient, confirmed by upregulated Treg markers, i.e., Foxp3, CTLA-4. APRIL significantly stimulates proliferation and survival of Tregs, whereas neutralizing anti-APRIL monoclonal antibodies (mAbs) inhibit these effects. Besides TACI-dependent induction of cell cycle progression and anti-apoptosis genes, APRIL specifically augments Foxp3, IL-10, TGFβ1, and PD-L1 in Tregs to further enhance Treg-inhibited Tcon proliferation. APRIL further increases MM cell-driven Treg (iTreg) via TACI-dependent proliferation associated with upregulated IL-10, TGFβ1, and CD15s in iTreg, which further inhibits Tcons. Osteoclasts producing APRIL and PD-L1 significantly block Tcon expansion by iTreg generation, which is overcome by combined treatment with anti-APRIL and anti-PD1/PD-L1 mAbs. Finally, APRIL increases IL-10-producing B regulatory cells (Bregs) via TACI on BM Bregs of MM patients. Taken together, these results define novel APRIL actions via TACI on Tregs and Bregs to promote MM cell survival, providing the rationale for targeting APRIL/TACI system to alleviate the immunosuppressive BM milieu and improve patient outcome in MM.
PMID: 30135465 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード